Humana Inc (HUM) Stock Price & Analysis
Humana Inc (HUM) fell 1.31% to USD 389.32 as of July 25, 2026 at 01:12 UTC, according to Nexqual real-time market data.
HUM last closed at USD 394.5; the session ranged USD 387.41–397.3 on volume of 740,260 shares. Market capitalization is —, with a 52-week range of USD 163.11–428.88 (NYQ). Source: Nexqual, July 25, 2026 at 01:12 UTC.
Key Statistics (as of July 25, 2026 at 01:12 UTC)
| Price | USD 389.32 |
|---|---|
| Change | ▼ 1.31% (down) |
| Previous Close | USD 394.5 |
| Open | USD 395.49 |
| Day Range | USD 387.41 – 397.3 |
| 52-Week Range | USD 163.11 – 428.88 |
| Volume | 740,260 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (HUM)
Nexqual's technical model rates HUM "BUY" based on 4 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 01:12 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 51.71 (neutral) |
| vs SMA50 | Above (USD 360.89) |
| MACD | 10.63 (positive) |
Analyst Ratings (HUM)
Wall Street analysts rate HUM "Buy" based on 24 analysts, with a mean price target of USD 347.96 (range USD 195–502), per Nexqual as of July 25, 2026 at 01:12 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 24 |
| Mean Target | USD 347.96 |
| High Target | USD 502 |
| Low Target | USD 195 |
| Buy / Hold / Sell | 9 / 15 / 2 |
Earnings (HUM)
| Next Earnings Date | 2026-07-29 |
|---|---|
| EPS Estimate | USD 7 |
| Revenue Estimate | $40.57B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 10.31 vs est 10.2 ▲ beat |
| 2025-12-31 | USD -3.96 vs est -3.99 ▲ beat |
| 2025-09-30 | USD 3.24 vs est 2.83 ▲ beat |
| 2025-06-30 | USD 6.27 vs est 5.87 ▲ beat |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Financials & Fundamentals (HUM)
| Total Revenue | $137.20B |
|---|---|
| Revenue Growth (YoY) | +23.50% |
| Gross Margin | +14.01% |
| Operating Margin | +4.67% |
| Profit Margin | +0.82% |
| ROE | +6.28% |
| Debt / Equity | 77.07 |
| Current Ratio | 1.77 |
| Total Cash | $21.97B |
| Total Debt | $14.37B |
| Free Cash Flow | $1.43B |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Financial Health Score (HUM)
Nexqual rates Humana Inc's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 01:12 UTC.
| Growth | Strong — Revenue +24% YoY (latest Q) |
|---|---|
| Profitability | Weak — Gross margin 14%, operating 5% |
| Balance Sheet | Mixed — $22.0B cash vs $14.4B debt, net cash position |
| Cash Flow | Mixed — FCF $1.43B, slim 1.0% margin |
| Efficiency | Mixed — ROE 6%, ROA 3.6% |
Ownership (HUM)
| Insider Ownership | +0.21% |
|---|---|
| Institutional Ownership | +99.90% |
| Float | 119.80M |
| Short % of Float | +4.10% |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Leadership (HUM)
Humana Inc is led by James A. Rechtin (age 54), President, CEO & Director, per Nexqual as of July 25, 2026 at 01:12 UTC.
| President, CEO & Director | James A. Rechtin (age 54) |
|---|---|
| Chief Financial Officer | Celeste Marie Mellet (age 48) |
| President of CenterWell | Sanjay K. Shetty (age 51) |
| Senior VP & CTO | Bobby Mukundan |
| Vice President of Investor Relations | Lisa M. Stoner |
Major Backers & Investors (HUM)
Notable institutional backers of Humana Inc include Dodge & Cox Inc., Pzena Investment Management LLC, Massachusetts Financial Services Co., according to Nexqual as of July 25, 2026 at 01:12 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Dodge & Cox Inc. | 15.77% |
| Pzena Investment Management LLC | 4.56% |
| Massachusetts Financial Services Co. | 3.73% |
| Sessa Capital IM, L.P. | 3.1% |
| JPMorgan | 2.53% |
| MFS SERIES TRUST I-MFS Value Fund | 1.4% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 20.21% |
| BlackRock | 9.81% |
| State Street | 5.75% |
| Geode Capital | 2.77% |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
From Humana Inc's Latest SEC 10-K Filing (filed 2026-02-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Humana Inc. provides medical and specialty insurance products in the United States.
- It operates in two segments, Insurance and CenterWell.
- Its CenterWell segment operates full-service, value-based senior focused primary care centers under the Conviva Senior Primary Care and CenterWell Senior Primary Care brands; a management services organization; CenterWell Home Health, a home health provider; and OneHome, which manages post-acute patient needs, as well as provides pharmacy and hospice solutions.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CI | The Cigna Group | USD 289.57 | ▲ 1.66% |
| CNC | Centene Corporation | USD 63.41 | ▼ 3.76% |
| HCA | HCA Healthcare, Inc. | USD 382.19 | ▲ 2.78% |
| UNH | UnitedHealth Group Incorporated | USD 420.74 | ▼ 2.45% |
| MCK | McKesson Corporation | USD 840.9 | ▲ 3.3% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:12 UTC. This page is informational and not investment advice.